The drugmaker has been viewed as a near-term takeover target for Big Pharma.
Add Axios as your preferred source to
see more of our stories on Google.
Illustration: Brendan Lynch/Axios
Abivax shares plunged more than 30% at Tuesday's open, after releasing troubling clinical data on its lead drug candidate.
Why it matters: The Paris-based drugmaker has been viewed as a near-term takeover target for Big Pharma.
Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
AbiVax falls as safety worries cloud ‘landmark’ immune drug results
Abivax Crashes Most On Record After Cancer Cases In Trial Data Spooks Wall Street
Abivax stock plunges on cancer signal in ulcerative colitis trial
Why Is Abivax Stock Sinking Tuesday? - Abivax (NASDAQ:ABVX)
Abivax ulcerative colitis drug shows strong efficacy, but cases of cancer raise concerns
Radiopharmaceutical shows promise in post-Pluvicto setting
Cancer cases weigh down Abivax’s Phase 3 maintenance data in ulcerative colitis
Analysts Are Bullish on These Healthcare Stocks: Biohaven Ltd. (BHVN), Abivax SA Sponsored ADR (ABVX)
A Parigi crolla Abivax, segnalati casi di cancro in studio clinico su farmaco
Analysts see the biotech company as a prime takeover target and several pharma giants have been rumored as potential buyers.
Shares of French biotech Abivax tumbled 32% after it reported fresh data on its lead asset.
A handful of cancer cases reported among treatment recipients overshadowed efficacy results analysts described as…
"The cancer signal complicates matters."
Jefferies downgraded the French biotech to Hold and cut its price target nearly in half, warning the cancer overhang won't…
Europe's best performing stock in 2025, Abivax, could be snapped up any day now, analysts say.
